Previous Article | Next Article 
J Virol, April 1998, p. 3098-3106, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Type D Retrovirus Capsid Assembly and Release Are
Active Events Requiring ATP
Robert A.
Weldon Jr.,1
William B.
Parker,2
Michael
Sakalian,1 and
Eric
Hunter1,*
Department of Microbiology, University of
Alabama at Birmingham, Birmingham, Alabama
35294,1 and
Southern Research
Institute, Birmingham, Alabama 352052
Received 3 October 1997/Accepted 12 January 1998
 |
ABSTRACT |
Mason-Pfizer monkey virus (M-PMV), the prototype type D retrovirus,
differs from most other retroviruses by assembling its Gag polyproteins
into procapsids in the cytoplasm of infected cells. Once assembled, the
procapsids migrate to the plasma membrane, where they acquire their
envelope during budding. Because the processes of M-PMV protein
transport, procapsid assembly, and budding are temporally and spatially
unlinked, we have been able to determine whether cellular proteins play
an active role during the different stages of procapsid morphogenesis.
We report here that at least two stages of morphogenesis require ATP.
Both procapsid assembly and procapsid transport to the plasma membrane
were reversibly blocked by treating infected cells with sodium azide
and 2-deoxy-D-glucose, which we show rapidly and reversibly
depletes cellular ATP pools. Assembly of procapsids in vitro in a
cell-free translation/assembly system was inhibited by the addition of
nonhydrolyzable ATP analogs, suggesting that ATP hydrolysis and not
just ATP binding is required. Since retrovirus Gag polyproteins do not
bind or hydrolyze ATP, these results demonstrate that cellular
components must play an active role during retrovirus morphogenesis.
 |
INTRODUCTION |
Assembly and release of nascent
retrovirus particles requires that the viral precursor polyproteins and
genomic RNAs, and certain host cell tRNAs, migrate to the plasma
membrane, where budding occurs. Two discrete intracellular transport
pathways are utilized during the assembly of the infectious virion. The viral glycoproteins are synthesized on membrane-bound polysomes and are
transported through the secretory pathway of the cell to the plasma
membrane, where they colocalize with the immature capsid during the
budding process (20). The major structural proteins of the
viral capsid and the enzymatic proteins are synthesized in the
cytoplasm on free polysomes and are transported to the underside of the
plasma membrane (13, 36). While many of the details of the
secretory pathway have been established, the mechanisms for
intracytoplasmic protein transport are poorly understood.
The major structural polyprotein (Gag) of a nascent retrovirus capsid
is encoded by the gag gene. Unlike most enveloped RNA viruses in which the viral glycoproteins mediate assembly by
stabilizing the interactions between the capsid proteins and the viral
membrane, retroviral Gag proteins can drive capsid assembly and budding in the absence of all the other viral gene products (19, 55, 58). As such, they contain all cis-acting information
necessary for intracytoplasmic transport, capsid assembly, membrane
binding, envelopment, and release from the cell surface. Assembly of
the immature retrovirus capsid begins shortly after the Gag
polyproteins are synthesized and modified by myristylation (15,
17, 40, 47-49). The Gag proteins of most retroviruses (the type
C avian and mammalian viruses, lentiviruses, and human T-cell leukemia virus/bovine leukemia virus-related viruses) migrate directly to the
plasma membrane, where they coalesce into spherical, immature capsids
and simultaneously bud through the lipid bilayer, thereby acquiring
their envelope. During or shortly after release, the Gag protein is
cleaved by the viral protease into the internal structural
(NH2-MA [matrix], CA [capsid], and NC [nucleocapsid]) proteins of the mature, infectious virion (22). In contrast, the Gag proteins of the mammalian and type B and D viruses (mouse mammary tumor virus [MMTV] and Mason-Pfizer monkey virus [M-PMV], respectively) accumulate in the cytoplasm, where they assemble into
spherical structures in the absence of membranes. These nascent particles have been referred to as intracytoplasmic type A particles, but by analogy to other viruses and bacteriophages, we have redefined them as procapsids (55). Once assembled, procapsids are
transported to the plasma membrane, from which they bud. Despite the
different assembly strategies, the processes whereby Gag proteins
assemble into procapsids are probably similar since a single amino acid change near the amino terminus of the Gag protein from M-PMV has been
shown to convert it to the type C morphogenic pathway (41).
Genetic analyses of the gag genes from different
retroviruses have shown that Gag proteins contain specific domains
which are required for capsid formation. A membrane binding (M) domain has been located at the amino-terminal end of Gag of several
retroviruses (31, 43, 60, 61). A late (L) domain functions
during the budding and release. In Rous sarcoma virus (RSV) and M-PMV,
the L domain is located between the MA and CA domains (57,
59). An equivalent domain in the lentiviruses has been found near
the carboxy terminus of the Gag precursor (34). A third
domain (I), located near the CA-NC junction, appears to be a region of
interaction between Gag proteins (3, 56). Despite the lack
of any extensive sequence similarities between different Gag proteins,
there is functional conservation between assembly domains. Chimeric Gag proteins containing the M, L, and I domains from different retroviruses can assemble into capsid-like structures and mediate budding at the
plasma membrane (3, 9, 10, 34).
The M-PMV Gag protein contains additional assembly elements which
influence procapsid assembly, stability, and transport. This virus
contains a region within Gag (known as p12) that is not found in either
the type C viruses or lentiviruses. It has been suggested from
biochemical data derived from studies with p12 deletion mutants that
this domain assists in assembly by stabilizing intermolecular Gag
associations (50). Protein stability and protein/procapsid
transport depend on sequences in the MA domain which appear to be
distinct from the M domain. As mentioned above, a single point mutation
in MA at residue 55 results in a Gag protein that no longer assembles
in the cytoplasm but rather assembles at the plasma membrane. This
mutation lies within an 18-amino-acid region of the MA domain that has
sequence similarity only to the type B retroviruses (41).
The nuclear magnetic resonance-derived solution structure of a
nonmyristylated M-PMV MA protein indicates that this region folds into
a structured turn which is solvent accessible in the monomer and trimer
models (8). Moreover, this structural feature is absent in
human immunodeficiency virus (HIV), simian immunodeficiency virus,
human T-cell leukemia virus, and bovine leukemia virus MA proteins
(7, 18, 27-30, 37). It is reasonable, therefore, to suspect
that this region contains a cytoplasmic protein transport signal which
must interact with a cellular factor. In contrast, other mutations in
either the myristic acid addition signal or at a variety of positions
elsewhere in the MA coding region result in Gag proteins that fail to
be released as virus-like particles despite assembling into procapsids in the cytoplasm (40, 43). Thus, the M-PMV Gag protein
appears to contain a second cytoplasmic transport signal which normally directs assembled procapsids and not unassembled Gag proteins to the
plasma membrane. It is implied in this model that the M-PMV Gag protein
must utilize multiple cellular components during the different stages
of assembly and release.
The type D retroviruses provide a useful system for studying
morphogenic events since procapsid assembly, protein transport, and
budding are temporally and spatially unlinked. We report here that in
infected cells and an in vitro translation/assembly system, procapsid
assembly and transport to the plasma membrane require ATP. Thus,
cellular proteins do play an active role during at least two stages of
M-PMV morphogenesis.
 |
MATERIALS AND METHODS |
Cells, viruses, and DNAs.
CMMT cells, which produce
infectious M-PMV, were initially established by cocultivating rhesus
mammary tumor cells with rhesus monkey embryo cells (1, 6).
Monolayers of CMMT cells were cultured in RPMI 1640 supplemented with
5% tryptose phosphate broth and 10% fetal bovine serum (regular
growth medium). For ATP depletion studies, cells were treated with 10 mM sodium azide and 6 mM 2-deoxy-D-glucose in glucose-free
RPMI 1640. Plasmid pTFCG (44) was used to program M-PMV Gag
polyprotein translations in vitro.
Radiolabeling.
Confluent monolayers of CMMT cells in
100-mm-diameter dishes were incubated for 20 min in methionine- and
cysteine-free RPMI 1640. Cells were then pulse-labeled for 30 min at
37°C with [35S]methionine-cysteine protein labeling mix
(0.2 mCi/ml, 1,175 Ci/mmol; NEN). In pulse-chase experiments,
pulse-labeled cells were chased for various times in either regular
growth medium or glucose-free RPMI 1640 containing the metabolic
inhibitors described above.
Cell lysis, immunoprecipitation, and gel electrophoresis.
The proportion of M-PMV Gag precursors that assembled into procapsids
was monitored at various times after labeling with
[35S]methionine-cysteine as described previously
(40, 50). Briefly, radiolabeled CMMT cells were lysed on ice
in TX-100 lysis buffer (0.25 M sucrose, 1.0 mM EDTA, 10 mM Tris-HCl
[pH 7.5], 0.14 M NaCl, 0.5% Triton X-100, 0.25% deoxycholate
[DOC]). Assembled M-PMV procapsids were separated from the bulk of
the cellular proteins by centrifugation through a 20% sucrose cushion
at 350,000 × g for 20 min at 4°C. The pellet was
lysed in 1 ml of 1× lysis buffer B (0.1% sodium dodecyl sulfate
[SDS], 1% Triton X-100, 1% DOC, 0.15 M NaCl, 0.05 M Tris-HCl [pH
7.5]). The supernatants containing unassembled Gag precursor
polyproteins were adjusted to 1× lysis buffer B by the addition of SDS
and DOC. Gag proteins present in the supernatant and pelleted fractions
were collected by immunoprecipitation using a rabbit
anti-Pr78gag antiserum (44).
Immunoprecipitates were dissolved in sample buffer (10% glycerol,
2.3% SDS, 63 mM Tris-HCl [pH 6.8], 5%
-mercaptoethanol, 0.01%
bromophenol blue), boiled for 4 min, separated on an SDS-12% polyacrylamide gel (54), and visualized by fluorography. The band intensities on the resulting fluorograms were quantitated by using
a high-performance digital imaging system and AlphaImager 2000 software
(Alpha Innotech Corp., San Leandro, Calif.). The intensities of each of
the Gag precursor proteins and their cleavage products (Pr95, p68, and
p27 [CA]) were normalized to Pr78gag
equivalents from their relative methionine content.
Measurement of ATP in cells.
The ATP levels in cells were
measured as described by Parker et al. (35). Briefly, 3 × 106 CMMT cells were collected by centrifugation and
incubated on ice for 10 min with 0.1 ml of ice-cold 0.5 M perchloric
acid. The acid-insoluble material was removed by centrifugation at
12,000 × g for 2 min. The supernatant was removed and
neutralized with 12.5 µl of 4 M KOH and 7.5 µl of 1 M potassium
phosphate (pH 7.5). Insoluble material was removed by centrifugation at
12,000 × g for 20 min, and the supernatant was
analyzed by high-pressure liquid chromatography (HPLC) using a
Partisil-10 SAX anion-exchange column. The nucleotides were eluted with
a 50-min linear gradient from 5 mM
NH4H2PO4 (pH 2.8) to 750 mM
NH4H2PO4 (pH 3.7) with a flow rate
of 2 ml/min. The nucleotides were detected by their absorbance at 254 nm. The concentrations of ATP in the samples were calculated by
comparison to known ATP standards.
Electron microscopy.
For analysis of procapsid assembly,
CMMT cells were fixed for 1 h in 1% glutaraldehyde in
phosphate-buffered saline (pH 7.0) at room temperature. The cells were
removed from the plates, washed several times in phosphate-buffered
saline, and then postfixed in 1% buffered osmium tetroxide for 1 h. The cells were rinsed again and then dehydrated with increasing
concentrations of ethanol beginning with 50% and ending with 100%.
The cells were rinsed three times with propylene oxide and then
embedded in Polybed. Ultrathin sections were made by using a
Rechert-Jung Ultra Cut E ultramicrotome. Sections were stained with
uranyl acetate and lead acetate, examined, and photographed in a
Hitachi-7000 transmission electron microscope.
Transcription, translation, and procapsid assembly in vitro.
Simultaneous transcription and translation reactions were performed
from plasmid pTFCG in the TNT coupled reticulocyte lysate system (Promega). For analysis of completed in vitro assembly reactions
by sucrose gradient analysis, lysates were diluted to a total volume of
100 µl with 30% (wt/wt) sucrose in 20 mM Tris (pH 8.0)-100 mM
NaCl-100 µM dithiothreitol-0.1% Triton X-100 (gradient buffer) and
loaded onto 2.2 ml continuous 30 to 55% (wt/wt) sucrose gradients in
gradient buffer. Gradients were centrifuged in a TLS-55 rotor (Beckman
Instruments) for 2 h at 55,000 rpm. Approximately 200-µl
fractions were taken by hand from the top of the gradient. The pellet
was suspended in 200 µl of 55% (wt/wt) sucrose in gradient buffer.
Aliquots (10 µl) of each fraction were dissolved in SDS sample buffer
and then loaded onto an SDS-12.5% polyacrylamide gel. After
polyacrylamide gel electrophoresis (PAGE), radioactive bands were
visualized by fluorography.
 |
RESULTS |
To determine whether M-PMV assembly, transport, and release are
active events that utilize cellular components and not merely passive
events such as diffusion and self-assembly, we asked whether viral
morphogenesis would still occur under conditions where cell-specific processes are inhibited. Since Gag proteins are not known to bind or
hydrolyze ATP, we specifically asked whether M-PMV procapsids could
assemble and bud from infected cells in the absence of ATP.
Sodium azide and 2-deoxy-D-glucose reversibly deplete
ATP levels in M-PMV-infected cells without affecting cell
viability.
It has been shown that short-term exposure of certain
cells to a combination of sodium azide and
2-deoxy-D-glucose can rapidly and reversibly deplete ATP
pools without adversely affecting cell viability (25, 53).
Given that the half times of procapsid assembly and release are ~45
min and 3.5 h, respectively (42, 43), we initially
determined whether these metabolic inhibitors were lethal to
M-PMV-infected (CMMT) cells within this time frame. CMMT cells were
incubated in either (i) normal growth medium, (ii) glucose-free,
serum-free medium, or (iii) glucose-free, serum-free medium containing
10 mM sodium azide and 6 mM 2-deoxy-D-glucose. In each
case, over 95% of the cells remained viable after 8 h when
examined by a trypan blue exclusion assay. When the drugs were replaced
after 4 h with normal growth medium and the cells were incubated
for an additional 24 h, more than 95% of the cells were viable
(data not shown).
To determine whether ATP could be depleted prior to the onset of
procapsid assembly and release, cells were treated with sodium azide
and 2-deoxy-D-glucose for various times. Equal numbers of cells were harvested, washed, and lysed according to established protocols (35). The amount of ATP present in lysates was
determined as described in Materials and Methods. As shown in Fig.
1, ATP levels dropped 4-fold within
1 h and more than 10-fold by 2 h. ATP remained at barely
detectable levels until the metabolic inhibitors were removed at 4 h. Approximately 2 h after removal of the drugs, ATP levels began
to rise, and by 12 h (8 h after inhibitors were removed), ATP
levels had risen to within 70% of the mock-treated control sample
levels.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of metabolic inhibitors on the ATP levels in
M-PMV-infected cells. CMMT cells were treated with 10 mM sodium azide
and 6 mM 2-deoxy-D-glucose for increasing amounts of time.
At various times, 3 × 106 cells were lysed and the
amounts of ATP were measured by HPLC anion-exchange chromatography. The
concentration of ATP in each sample was calculated based on the
concentrations of known ATP standards.
|
|
ATP depletion inhibits procapsid assembly and blocks virus
release.
Having shown that the cellular ATP pools were rapidly and
reversibly depleted in the presence of the drugs, we asked whether assembly, transport, or release could occur in the absence of ATP. CMMT
cells were pulse-labeled without drugs for 20 min. The rates at which
these labeled Gag proteins were chased into procapsids and virus in
either the absence or presence of the metabolic inhibitors were
examined. CMMT cells produce three Gag-related polyproteins of 78, 95, and 180 kDa. The most abundant of these is the 78-kDa Gag polyprotein
(Pr78gag). The 95- and 180-kDa proteins are the
Gag-Pro (Pr95gag-pro) and Gag-Pro-Pol
(Pr180gag-pro-pol) proteins which are
synthesized via ribosomal frameshifting events. All three precursors
are incorporated into procapsids and virions, but
Pr180gag-pro-pol is made in very low amounts and
is often difficult to detect by radiolabeling (see below). A smaller
Gag-related protein of 68 kDa (p68) is also detected in M-PMV-infected
cells. This protein originates from translational initiation from the
second methionine codon in gag which is located at the end
of the MA coding region (39).
As shown in Fig.
2 (lanes 1 to 3), the
Gag precursor polyproteins Pr78
gag,
Pr95
gag-pro, and p68 were detected in both the
soluble and pelleted fractions
of pulse-labeled cells. These two
fractions have been shown previously
to contain unassembled Gag
proteins and assembled procapsids,
respectively (
42). Of the
total amount of these Gag precursors
in pulse-labeled cells, 38% had
already assembled into procapsids
(Fig.
3A). No proteins were found in the virus
pellet fraction
at the end of the pulse-label. Following a 2-h chase in
the absence
of drugs, the total amount of cell-associated Gag
precursors (both
unassembled and assembled) had dropped to
approximately 40% of
that detected in the pulse (Fig.
3A). Of this
amount, 65% was
found in the procapsid-associated fraction. The
decrease in cell-associated
Gag proteins was primarily due to virus
release rather than degradation
since the total amount of Gag
precursors and processed CA equivalents
(normalized to
Pr78
gag equivalents based on methionine content)
present in the cells
and in virus is 95% of that in the pulse (Fig.
3C).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 2.
Kinetics of M-PMV procapsid assembly and virus release
in the presence of the metabolic inhibitors. CMMT cells were
pulse-labeled with [35S]methionine and cysteine for 20 min (lanes 1 to 3) and then chased for 2 h (lanes 4 to 9) and
4 h (lanes 10 to 15) in the absence (lanes 4 to 6 and 10 to 12) or
presence of 10 mM sodium azide and 6 mM 2-deoxy-D-glucose
(lanes 7 to 9 and 13 to 15). Cells were fractionated in TX-100 lysis
buffer by centrifugation as described in Materials and Methods. Gag
proteins present in the soluble (S [unassembled molecules]; lanes 1, 4, 7, 10, and 13) and pelleted fractions (P [assembled procapsids];
lanes 2, 5, 8, 11, and 14) and in virus (V; lanes 3, 6, 9, 12, and 15)
were immunoprecipitated with anti-Pr78gag
polyclonal serum. The positions of the molecular mass protein markers
are indicated, as are the positions of Pr78gag
and CA.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Graphic representation of the effects of metabolic
inhibitors on M-PMV morphogenesis. The fluorograms shown in Fig. 2 and
4 were quantitated as described in Materials and Methods, and the band
intensities of the Gag precursor polyproteins
Pr95gag-pro, Pr78gag, and
p68 as well as the processed p27 (CA) were normalized to
Pr78gag equivalents with respect to their
methionine content. The percentages of the total
Pr78gag equivalents present in the soluble
(solid bars) and pelleted fractions (open bars) and in virus pellets
(cross-hatched bars) at each time point during the mock treatment (A)
and drug treatment (B) are shown. (C) The amounts of
Pr78gag equivalents in the soluble and pelleted
lysate fractions and in the viral pellets at each time point were
combined and are reported as the percentage of the initial
pulse-labeled Gag proteins.
|
|
At the end of the 2-h chase, significant amounts of the 27-kDa mature
CA were found in both cell lysates and virus. The CA
protein is derived
from Gag following the action of the viral
protease. This processing of
Gag takes place during or shortly
after budding at the plasma membrane.
Mutations that block transport
to or budding from the plasma membrane
prevent Gag processing
(
40,
43). The presence of CA in the
cell-associated fraction
is therefore a measure of virus budding and
probably represents
virus particles that have budded from the plasma
membrane but
remain cell associated during the fractionation protocol.
Finding
the majority of the cell-associated CA in the soluble fraction
is common since cleaved Gag proteins in mature virions are easily
solubilized with detergent (
51). After the 4-h chase, only
17%
of the pulse-labeled Gag precursors remained cell associated;
of
this amount, the majority (80%) fractionated with procapsids
(Fig.
2,
lanes 10 to 12; Fig.
3A). The reduction in total cell-associated
Gag
precursors and the increase in assembled procapsids were accompanied
by
increasing amounts of CA associated with cells and virus pellets.
The
kinetics of M-PMV procapsid assembly and release in CMMT cells
(half-lives of 1 h and 3 to 4 h, respectively) are consistent
with that previously observed in COS-1 and HeLa cells (
43).
In contrast to normal virus morphogenesis, procapsid assembly and virus
release were dramatically inhibited in cells treated
with sodium azide
and 2-deoxy-
D-glucose. After 2 h of drug treatment,
99% of the Gag precursors present in the pulse-labeled cells could
still be precipitated from the cell lysates (combined soluble
and
pelleted fractions) with the polyclonal antiserum (Fig.
3C).
As was
seen in the pulse-labeled cell extracts, approximately
40% of the
radiolabeled Gag proteins had assembled into procapsids
(Fig.
2, lanes
7 and 8; Fig.
3B). In contrast to the results observed
after the 2-h
chase in the absence of drugs, no Gag cleavage products
were detected
in either the cell lysates or virus pellets (Fig.
2, lanes 7 to 9). The
absence of CA in these fractions suggests
that those procapsids that
had assembled during the pulse and
the early time points of drug
treatment did not reach the stage
of budding from the plasma membrane.
After 4 h of drug treatment,
virtually 100% of the pulse-labeled
Gag precursors could still
be detected in the cell lysates (Fig.
3C).
After subtracting the
nonspecific and abnormally high background from
the pelleted fraction
(Fig.
2, lane 14), we found that the amount of
cell-associated
Gag which had assembled into procapsids had risen
slightly to
48% (Fig.
3B). These procapsids, however, were not
released from
the cell as virus particles (Fig.
2, lane 15). Since Gag
proteins
are not known to bind or hydrolyze ATP, these results suggest
that procapsid assembly and either protein transport to the plasma
membrane or budding/release rely on cellular proteins that utilize
ATP.
Restoration of assembly and release by removing the metabolic
inhibitors.
If the hypothesis that procapsid assembly, transport,
and/or membrane associations is ATP dependent is correct, it would be reasonable to expect that these processes would resume if the cells
were allowed to regenerate ATP. To examine this, parallel monolayers of
pulse-labeled cells were chased in the absence or presence of drugs as
described above except that after 4 h, the metabolic block was
removed by replacing the drug-containing medium with normal growth
medium. Cells were fractionated, and virus particles that had
accumulated during the initial 4-h chase (Fig. 4, lanes Va) and during the following
chase (Vb) were analyzed. After a 6-h chase in the absence of the
drugs, more than 95% of the pulse-labeled Gag proteins had been
processed (Fig. 3A), and approximately 50% of these were released as
free virus particles (Fig. 4A, lanes 1 to 4). Mature virions remained
associated with cells even after a 12-h chase, when 32% of the CA
protein was found in the cell lysates (Fig. 4B, lanes 5 to 8).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Restoration of M-PMV morphogenesis by removing the
metabolic block. Plates of CMMT cells identical to those used for Fig.
2 were pulse-labeled for 20 min and then chased in the absence (A,
lanes 1 to 4 and 9 to 12; B, lanes 5 to 8) or presence of 10 mM sodium
azide and 6 mM 2-deoxy-D-glucose (A, lanes 5 to 8; B, lanes
1 to 4 and 9 to 12) for 4 h. The culture media were replaced with
normal growth medium without drugs, and the cells were further
incubated for either 2 h (A, lanes 1 to 8), 4 h (A, lanes 9 to 12; B, lanes 1 to 4), or 8 h (B, lanes 5 to 12). Gag-specific
proteins present in virus that had accumulated in the culture media
during the initial 4-h chase (lanes Va) and the subsequent chase (Vb)
and in the soluble (S) and pelletable (P [assembled procapsids])
fractions of cell lysates were immunoprecipitated with
anti-Pr78gag polyclonal serum.
|
|
In the drug-treated plates, the block to procapsid assembly and release
was relieved by removing the metabolic inhibitors.
The amount of the
labeled Gag precursors that remained soluble
(40%) 2 h after the
drugs were removed was less than that seen
(52%) after 4 h of
continuous drug treatment. This decrease in
soluble Gag was accompanied
by an increase in procapsid assembly
but not virus budding (Fig.
4A,
lanes 5 to 8; Fig.
3B). Four hours
after the drugs were removed, the
amount of unassembled Gag (23%)
had decreased and there was a
significant increase in the cell-associated
and virus-associated CA
protein (Fig.
4B, lanes 1 to 4). These
changes are consistent with the
rise in ATP levels after the drugs
were removed (Fig.
1). By the point
at which ATP levels had risen
to within 70% of that of mock-treated
cells (8 h after removal
of the drugs), only 26% of pulse-labeled Gag
precursors were found
to be cell associated. The remainder of the Gag
proteins had been
processed into CA; of these, >70% were found in the
virus pellets
(Fig.
4B, lanes 9 to 12; Fig.
3B). The relative
difference in
the amount of Gag proteins present in the various
fractions was
not due to protein degradation but rather was due to
renewed procapsid
assembly and virion release since the total amount of
labeled
Pr78
gag equivalents that was
immunoprecipitated with the polyclonal antisera
varied by <25% of
that detected after the initial pulse-labeling
(Fig.
3C).
In vitro assembly of M-PMV procapsids is dependent on ATP.
To
further confirm our observation that M-PMV procapsid assembly requires
ATP, we assayed whether Pr78gag could assemble
into procapsids in vitro in the presence of a nonhydrolyzable ATP
analog, ATP
S. We have shown previously that Pr78gag and Pr95gag-pro
proteins can assemble in vitro into procapsid-like structures which are
indistinguishable in density and appearance from authentic procapsids
produced in mammalian cells (44). Furthermore, since we have
shown that anti-Gag monoclonal antibodies can inhibit assembly, this
system is suitable for testing potential inhibitors of this process.
Coupled transcription and translation of Pr78gag
and Pr95gag-pro was initiated in reticulocyte
lysates and allowed to proceed for 30 min at 30°C to allow enough
time for sufficient protein synthesis. At that time, cycloheximide and
either ATP
S or water were added to the reaction mixture. The lysate
was then incubated for an additional 90 min, after which the reactions
were analyzed for procapsid assembly by gradient analysis and SDS-PAGE
(Fig. 5). The absence of
Pr78gag and Pr95gag-pro
in the middle of the density gradient shows that the addition of
ATP
S completely inhibited procapsid assembly (Fig. 5, top panel). In
contrast, ~50% of the Pr78gag and
Pr95gag-pro precursors had assembled into
procapsids that sedimented to a density of ~1.2 g/ml in control
samples (Fig. 5, bottom panel). Identical results were obtained with
the similar nonhydrolyzable ATP analog AMP-PNP (data not shown). These
data demonstrate that ATP hydrolysis and not just ATP binding is
required for procapsid assembly.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 5.
Sucrose gradient analysis of M-PMV gag and
gag-pro programmed in vitro translations. Equal volumes of
gradient fractions were separated by SDS-PAGE (10% polyacrylamide gel)
and visualized by fluorography. Lane numbers represent the gradient
fractions beginning from the top (lane 1). Lane L contained an
equivalent aliquot of the translation reaction mixture which was loaded
onto each gradient; lane P contained the material which had pelleted in
the tube. The electrophoretic positions of the molecular mass protein
markers are indicated in kilodaltons on the left, and the positions of
Pr78gag and Pr95gag-pro
are shown on the right. The translation reactions which were treated
with ATP S (top panel) or H2O (control; bottom panel) are
indicated.
|
|
Analysis of procapsid transport and membrane associations by
electron microscopy.
While the in vitro data demonstrated that
procapsid assembly requires ATP, the data from the pulse-chase
experiments in the presence of the metabolic inhibitors indicated that
a postassembly step was also dependent upon ATP. However, it was not
possible to distinguish whether (i) transport of assembled procapsids
to the plasma membrane, (ii) stable associations between the procapsids and the membrane, or (iii) budding was the ATP-dependent step. To
discriminate between these possibilities, mock-treated and drug-treated
cells were directly examined by electron microscopy. If procapsid
transport was inhibited in the presence of the drugs, then one would
expect to find a majority of the capsids in the cytoplasm and not
associated with membranes. If either membrane association or budding
was inhibited and procapsid transport was not, the majority of the
procapsids would be expected to localize near the plasma membrane.
Numerous procapsids clustered in the cytoplasm and associated with the
plasma membrane were detected in mock-treated cells
(Fig.
6A and
B). The cytoplasmic procapsids and
budding particles
clearly display the electron-dense doughnut shape
characteristic
of immature retrovirus cores. These structures were
easily identified
in essentially every cell examined. In contrast,
detection of
cytoplasmic procapsids and especially membrane-associated
procapsids
in drug-treated cells became progressively harder the longer
the
cells were treated. In cells that were treated for 1.5 h (Fig.
6C), several cytoplasmic procapsids were detected in approximately
half
of the cells (
n 
100 cells) that were examined.
However,
no membrane-associated forms were found. As shown, a few
cell-free
virus particles were found in these samples, but these
displayed
a morphology characteristic of mature particles (i.e.,
electron-dense
cores). These particles were more than likely released
from the
cell prior to ATP depletion since the pulse-chase data
demonstrated
that particle release and Gag processing were inhibited in
the
presence of the inhibitors. After 3 h of drug treatment,
~40%
of the cells (
n 
200 cells) contained
cytoplasmic procapsids.
Out of all of these cells, only one
membrane-associated procapsid
was found (Fig.
6E). In contrast,
multiple membrane-associated
procapsids were found in cells that had
been treated with drugs
for 3 h and then incubated in their
absence for 90 min (Fig.
6F
and G). These data are consistent with the
pulse-chase experiments
(i.e., absence of cell-associated CA in the
drug-treated cell
lysates), and they indicate that transport of
assembled procapsids
to the plasma membrane is ATP dependent.

View larger version (135K):
[in this window]
[in a new window]
|
FIG. 6.
Electron micrographs of CMMT cells treated with the
metabolic inhibitors. Thin sections of CMMT cells which had been mock
treated or drug treated were examined by electron microscopy to
determine at which stage processed assembly or release was arrested. (A
and B) Sections of mock-treated cells; (C to G) sections of cells
treated with drugs for 1.5 h (C), treated with drugs for 3 h
(D and E), and treated with drugs for 3 h and then without drugs
for 1.5 h (F and G). Arrow, cytoplasmic procapsids; arrowheads,
budding virions. Magnification, ×51,000; bars, approximately 100 nm.
|
|
 |
DISCUSSION |
According to current models, release of a type D retrovirus
particle requires at least six distinct posttranslational events: (i)
transport of nascent Gag proteins from their sites of synthesis to the
defined assembly domains in the cytoplasm, (ii) assembly of the
procapsid, (iii) transport of the assembled procapsid through the
cytoplasm to the plasma membrane, (iv) membrane binding, (v) capsid
envelopment and budding, and (vi) membrane fusion to release the virus
particle. Based on genetic evidence, some of these events are thought
to be dependent on host cell factors. The ability of a single point
mutation in the MA domain (R55W) to alter the site of assembly from the
cytoplasm to the plasma membrane suggests that wild-type Gag proteins
arrive at the cytoplasmic assembly sites by a specific transport
mechanism (41). Certain point mutations elsewhere in the MA
domain result in the accumulation of procapsids in the cytoplasm
(40, 43). Transport of these mutant procapsids to the plasma
membrane is apparently blocked. Taken together, the phenotypes of these
mutants suggest that transport to and transport from the cytoplasmic
assembly sites are both active processes driven by cellular components
rather than a passive process such as diffusion. The data presented in
this report not only support the concept of active transport through
the cytoplasm but also provide evidence that cellular factors play an
active role during procapsid assembly.
Pulse-chase experiments in conjunction with cell fractionation studies
which separate unassembled (soluble) Gag proteins from assembled
procapsids indicate that procapsid assembly can be inhibited with the
metabolic inhibitors sodium azide and 2-deoxy-D-glucose. During the pulse-labeling, a significant proportion of the nascent Gag
molecules had been incorporated into procapsids that could be pelleted
by centrifugation. This was expected since previous work had shown that
in HeLa cells and COS-1 cells which express the M-PMV Gag polyprotein,
half of the newly synthesized Gag proteins are incorporated into
procapsids within 45 min (42, 43). In the absence of drugs,
there was a steady increase in procapsid-associated and
virus-associated Gag during the chases. In contrast, the amount of
pulse-labeled Gag that fractionated with assembled procapsids in the
presence of drugs rose only slightly, and none was found associated
with released virus. In fact, the block to assembly occurred within the
amount of time it took for the drugs to deplete the ATP pools
approximately fourfold. The ability to block assembly in vitro with
nonhydrolyzable ATP analogs demonstrates that assembly itself requires
ATP hydrolysis. Since these experiments focus on the assembly process
itself, it is entirely possible that transport of newly synthesized Gag
proteins to the assembly sites also requires ATP.
Because chaperonins facilitate protein folding in an ATP-dependent
manner (16, 52), the requirement for ATP during M-PMV procapsid assembly raises the possibility that cytosolic chaperonins play an active role during procapsid morphogenesis. Such a role for
chaperone-assisted capsid assembly has been demonstrated with hepatitis
B virus (HBV). Lingappa et al. (24) found that HBV core
proteins translated in vitro could assemble into structures which
closely resembled authentic HBV cores. They also demonstrated, using
sucrose gradients and coimmunoprecipitation experiments, that a
significant portion of the HBV core proteins colocalized with CC60 (a
TCP-1-related chaperone) in an ATP-dependent manner. TCP-1 is a subunit
of a large hetero-oligomeric ring complex (CCT/TRiC) consisting of two
rings of eight 55-kDa subunits (14, 16). Like other
chaperones, TRiC mediates protein folding and requires ATP for the
release of its substrate. Clearly the association of a substrate
protein with TRiC would result in a complex that could be easily
pelleted by centrifugation. In fact, HBV core proteins associated with
CC60 were found at the bottom of sucrose gradients. Also, the HBV core
protein could be chased out of the pellet (CC60 complex) and into
fractions containing either HBV capsids or unassembled core proteins by
manipulating the energy substrates (i.e., by addition of nucleoside
triphosphates or apyrase) of the in vitro extracts. We have also found
in vitro-translated M-PMV Gag proteins in the pellets of sucrose
gradients (44). However, unlike the HBV core protein, the
pelleted M-PMV protein appears to assemble into aberrant, dead-end
structures that bear no resemblance to M-PMV capsids or TRiC ring-like
structures. Since ATP is required to release substrate polypeptides
from the TRiC complex, it would be expected that under limited ATP
conditions, there would be an increase in the substrate-TRiC complex.
To this end, addition of nonhydrolyzable ATP analogs to the in vitro
translation resulted in an increase of material at the top of the
gradient and not in the pellet. Thus, it is unlikely that Gag interacts with TCP-1. Other candidate cytosolic chaperones include the
Hsp70/Hsp90 family. Determination of whether these cellular proteins
assist in procapsid assembly awaits further experimentation.
The requirement for ATP during M-PMV procapsid assembly is not
inconsistent with previous results which demonstrated that other
retroviral Gag proteins can be purified and assembled into capsid-like
structures under appropriate conditions without an apparent need for
ATP. Campbell and Vogt have shown that RSV and HIV Gag proteins can be
overexpressed in and purified from bacteria in a soluble form (4,
5). By manipulating the pH and ionic strength and by including
RNA in the assembly reaction, it was shown that these proteins could
self-assemble into spherical capsid-like structures. Since the RSV and
HIV Gag proteins remained soluble in bacteria rather than accumulating
in inclusion bodies, it is entirely possible that these proteins had
been properly folded into assembly-competent forms by bacterial
chaperone proteins prior to their purification. Thus, the requirement
for ATP had already been met. In contrast, overexpression of the M-PMV
Gag protein in bacteria results in the accumulation of capsid-like structures in inclusion bodies (21). Purification of Gag
from the insoluble inclusion bodies required denaturation using 8 M urea. However, such denatured Gag proteins could be renatured and
assembled into capsid-like structures by slowly removing the urea under
the correct pH and ionic strength. This slow, controlled renaturation
of Gag could conceivably supersede the proposed requirement for
ATP-dependent (chaperone-assisted) protein folding.
ATP-dependent assembly is not unique to the type D retroviruses.
Lingappa et al. (23) demonstrated that HIV type 1 (HIV-1) Gag proteins translated in vitro can assemble into capsids in a wheat
germ extract but only in the presence of ATP. They further showed that
assembly is dependent on both a detergent-insoluble and a
detergent-soluble component present in the extracts. However, since
capsid assembly and budding occur concomitantly during lentivirus morphogenesis and probably during assembly in vitro, it is difficult to
distinguish at which step these cellular factors are being utilized. In
contrast, we have shown directly that ATP hydrolysis is a prerequisite
for the assembly of precursor proteins into the procapsid shell. In
addition, we present several lines of evidence that assembled M-PMV
procapsids arrive at the plasma membrane by an active process rather
than by passive diffusion. While a portion of the nascent Gag proteins
had assembled into procapsids during the pulse-labeling, these proteins
failed to be released as virus particles upon ATP depletion. Based on
the absence of cell-associated CA during the drug treatment and on the
absence of membrane-associated procapsids in the electron micrographs,
the block to particle release appears to occur prior to membrane
binding. To this end, the phenotype of the procapsids during the drug
treatment resembles that of the transport-defective mutant, A18V
(43). Cells expressing this mutant contain an array of
procapsids in the cytoplasm but none in association with the plasma
membrane. Furthermore, the absence of cell-associated CA in
A18V-expressing cells or in cells expressing a variety of other mutants
that are incapable of budding from the plasma membrane indicates that
the viral protease becomes active after binding the plasma membrane,
perhaps during either envelopment or release. Based on the recent
nuclear magnetic resonance-derived solution structure of a
nonmyristylated M-PMV MA protein, the arginine at residue 18 lies
within an alpha helix which has been proposed to be located on the
membrane-proximal surface of the MA monomer and trimer models
(8). Provided that a similar structural motif exists in the
context of the myristylated Gag polyprotein, this region would be
solvent accessible and therefore available to associate with the
cellular transport machinery. This phenotypic similarity between the
transport-defective procapsids and what was observed with wild-type
procapsids during ATP depletion provides strong evidence that transport
to the plasma membrane is an active process requiring recognition of
procapsid structural elements by cellular components.
It has been suggested that elements of the cytoskeleton may provide a
motive force for delivering certain Gag molecules to the site of
assembly or for budding. Actin has been found in purified HIV-1 and
MMTV virions (2, 32), and cell fractionation studies of
HIV-1 and murine leukemia virus-infected cells have shown that Gag
proteins cosediment with detergent-insoluble material which contains
cytoskeletal proteins and membrane components (11, 12, 26,
38). Furthermore, the efficiency of HIV-1, MMTV, and Moloney
murine leukemia virus particle release can be diminished (but not
completely blocked) pharmacologically by using cytochalasins, colchicine, and wortmannin (26, 33, 38, 45, 46). These data
suggest that the cytoskeleton may play a role during capsid morphogenesis. However, a specific interaction between the cytoskeleton and Gag that is relevant to protein/procapsid transport or assembly has
not yet been demonstrated. Based on the electron micrographs presented
in this report as well as on numerous others of M-PMV (both published
and unpublished), we have not observed procapsids in close association
with either cytoskeletal elements or membranes other than the plasma
membrane. Nonetheless, we are exploring whether microtubule or
microfilament destabilization has any effect on the efficiency or the
rate of M-PMV procapsid assembly and release.
 |
ACKNOWLEDGMENTS |
We are grateful to Eugene Arms and Dale Abrahamson at the UAB
Comprehensive Cancer Center Electron Microscopy Core Facility for
excellent assistance with electron microscopy and to Lucy M. Rose at
the Southern Research Institute (Birmingham, Ala.) for assistance in
ATP quantitations. We also thank Sally Weldon and John West for
critical reading of the manuscript.
This work was supported by Public Health Service grants AI09054 to
R.A.W., AI29157 to W.B.P., AI093001 to M.S., and CA-27834 to E.H.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, 256 BBRB, 845 19th St. So., Birmingham, AL 35294-2170. Phone: (205) 934-4321. Fax: (205) 934-1640. E-mail:
eric_hunter{at}microbio.uab.edu.
 |
REFERENCES |
| 1.
|
Ahmed, M.,
S. A. Mayyasi,
H. C. Chopra,
I. Zelljadt, and E. M. Jensen.
1971.
Mason-Pfizer monkey virus isolated from spontaneous mammary carcinoma of a female monkey. I. Detection of virus antigens by immunodiffusion, immunofluorescent, and virus agglutination techniques.
J. Natl. Cancer Inst.
46:1325-1334.
|
| 2.
|
Arthur, L. O.,
J. Bess, Jr.,
R. C. Sowder II,
R. E. Benveniste,
D. L. Mann,
J. C. Chermann, and L. E. Henderson.
1992.
Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.
Science
258:1935-1938[Abstract/Free Full Text].
|
| 3.
|
Bennett, R. P.,
T. D. Nelle, and J. W. Wills.
1993.
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
67:6487-6498[Abstract/Free Full Text].
|
| 4.
|
Campbell, S., and V. M. Vogt.
1995.
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.
J. Virol.
69:6487-6497[Abstract].
|
| 5.
|
Campbell, S., and V. M. Vogt.
1997.
In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.
J. Virol.
71:4425-4435[Abstract].
|
| 6.
|
Chopra, H. C., and M. M. Mason.
1970.
A new virus in a spontaneous mammary tumor of a rhesus monkey.
Cancer Res.
30:2081-2086[Abstract/Free Full Text].
|
| 7.
|
Christensen, A. M.,
M. A. Massiah,
B. G. Turner,
W. I. Sundquist, and M. F. Summers.
1996.
Three-dimensional structure of the HTLV-II matrix protein and comparative analysis of matrix proteins from the different classes of pathogenic human retroviruses.
J. Mol. Biol.
264:1117-1131[Medline].
|
| 8.
|
Conte, M. R.,
M. Klikova,
E. Hunter,
T. Ruml, and S. Matthews.
1997.
The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus.
EMBO J.
16:5819-5826[Medline].
|
| 9.
|
Deminie, C. A., and M. Emerman.
1993.
Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions.
J. Virol.
67:6499-6506[Abstract/Free Full Text].
|
| 10.
|
Deminie, C. A., and M. Emerman.
1994.
Functional exchange of an oncoretrovirus and a lentivirus matrix protein.
J. Virol.
68:4442-4449[Abstract/Free Full Text].
|
| 11.
|
Edbauer, C. A., and R. B. Naso.
1983.
Cytoskeleton-associated Pr65gag and retrovirus assembly.
Virology
130:415-426[Medline].
|
| 12.
|
Edbauer, C. A., and R. B. Naso.
1984.
Cytoskeleton-associated Pr65gag and assembly of retrovirus temperature-sensitive mutants in chronically infected cells.
Virology
134:389-397[Medline].
|
| 13.
|
Eisenman, R. N.,
V. M. Vogt, and H. Diggelmann.
1974.
Synthesis of avian RNA tumor virus structural proteins.
Cold Spring Harbor Symp. Quant. Biol.
39:1067-1075[Abstract/Free Full Text].
|
| 14.
|
Frydman, J.,
E. Nimmesgern,
H. Erdjument-Btomage,
J. S. Wall,
P. Tempst, and F. Hartl.
1992.
Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits.
EMBO J.
11:4767-4778[Medline].
|
| 15.
|
Göttlinger, H. G.,
J. G. Sodroski, and W. A. Haseltine.
1989.
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type I.
Proc. Natl. Acad. Sci. USA
86:5781-5785[Abstract/Free Full Text].
|
| 16.
|
Hartl, F. U.
1996.
Molecular chaperones in cellular protein folding.
Nature
381:571-579[Medline].
|
| 17.
|
Henderson, L. E.,
H. C. Krutzsch, and S. Oroszlan.
1983.
Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational protein modification.
Proc. Natl. Acad. Sci. USA
80:339-443[Abstract/Free Full Text].
|
| 18.
|
Hill, C. P.,
D. Worthylake,
D. P. Bancroft,
A. M. Christensen, and W. I. Sundquist.
1996.
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.
Proc. Natl. Acad. Sci. USA
93:3099-3104[Abstract/Free Full Text].
|
| 19.
|
Hunter, E.
1994.
Macromolecular interactions in the assembly of HIV and other retroviruses.
Semin. Virol.
5:71-83.
|
| 20.
|
Hunter, E., and R. Swanstrom.
1990.
Retrovirus envelope glycoproteins.
Curr. Top. Microbiol. Immunol.
157:187-254[Medline].
|
| 21.
|
Klikova, M.,
S. S. Rhee,
E. Hunter, and T. Ruml.
1995.
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria.
J. Virol.
69:1093-1098[Abstract].
|
| 22.
|
Leis, J.,
D. Baltimore,
J. M. Bishop,
J. Coffin,
E. Fleissner,
S. P. Goff,
S. Oroszlan,
H. Robinson,
A. M. Skalka,
H. M. Temin, and V. Vogt.
1988.
Standardized and simplified nomenclature for proteins common to all retroviruses.
J. Virol.
62:1808-1809[Abstract/Free Full Text].
|
| 23.
|
Lingappa, J. R.,
R. L. Hill,
M. L. Wong, and R. S. Hegde.
1997.
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system.
J. Cell Biol.
136:567-581[Abstract/Free Full Text].
|
| 24.
|
Lingappa, J. R.,
R. L. Martin,
M. L. Wong,
D. Ganem,
W. J. Welch, and V. R. Lingappa.
1994.
A eukaryotic cytosolic chaperonin is associated with a high molecular weight intermediate in the assembly of hepatitis B virus capsid, a multimeric particle.
J. Cell Biol.
125:99-111[Abstract/Free Full Text].
|
| 25.
|
MacDonald, H. R., and C. J. Kock.
1977.
Energy metabolism and T-cell-mediated cytolysis.
J. Exp. Med.
146:698-709[Abstract/Free Full Text].
|
| 26.
|
Maldarelli, F.,
N. W. King, Jr., and M. J. Yagi.
1987.
Effects of cytoskeletal disrupting agents on mouse mammary tumor virus replication.
Virus Res.
7:281-295[Medline].
|
| 27.
|
Massiah, M. A.,
M. R. Starich,
C. Paschall,
M. F. Summers,
A. M. Christensen, and W. I. Sundquist.
1994.
Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein.
J. Mol. Biol.
244:198-223[Medline].
|
| 28.
|
Matthews, S.,
P. Barlow,
J. Boyd,
G. Barton,
R. Russell,
H. Mills,
M. Cunningham,
N. Meyers,
N. Burns,
N. Clark,
S. Kingsman,
A. Kingsman, and I. Campbell.
1994.
Structural similarity between the p17 matrix protein of HIV-1 and interferon-gamma.
Nature
370:666-668[Medline].
|
| 29.
|
Matthews, S.,
P. Barlow,
N. Clark,
S. Kingsman,
A. Kingsman, and I. Campbell.
1995.
Refined solution structure of p17, the HIV matrix protein.
Biochem. Soc. Trans.
23:725-729[Medline].
|
| 30.
|
Matthews, S.,
M. Mikhailov,
A. Burny, and P. Roy.
1996.
The solution structure of the bovine leukemia virus matrix protein and similarity with lentiviral matrix proteins.
EMBO J.
15:3267-3274[Medline].
|
| 31.
|
Nelle, T. D., and J. W. Wills.
1996.
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity.
J. Virol.
70:2269-2276[Abstract].
|
| 32.
|
Ott, D. E.,
L. V. Coren,
B. P. Kane,
L. K. Busch,
D. G. Johnson,
R. C. Sowder II,
E. N. Chertova,
L. O. Arthur, and L. E. Henderson.
1996.
Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.
J. Virol.
70:7734-7743[Abstract].
|
| 33.
|
Panem, S.
1977.
Cell cycle-dependent inhibition of Kirsten murine sarcoma-leukemia virus release by cytochalasin B.
Virology
76:146-151[Medline].
|
| 34.
|
Parent, L. J.,
R. P. Bennett,
R. C. Craven,
T. D. Nelle,
N. K. Krishna,
J. B. Bowzard,
C. B. Wilson,
B. A. Puffer,
R. C. Montelaro, and J. W. Wills.
1995.
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
69:5455-5460[Abstract].
|
| 35.
|
Parker, W. B.,
S. C. Shaddix,
C. H. Chang,
E. L. White,
L. M. Rose,
R. W. Brockman,
A. T. Shortnacy,
J. A. Montgomery,
J. Secrist, and L. Bennett, Jr.
1991.
Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Cancer Res.
51:2386-2394[Abstract/Free Full Text].
|
| 36.
|
Purchio, A. F.,
S. Jovanovich, and R. L. Erikson.
1980.
Sites of synthesis of viral proteins in avian sarcoma virus-infected chicken cells.
J. Virol.
35:629-636[Abstract/Free Full Text].
|
| 37.
|
Rao, Z.,
A. S. Belyaev,
E. Fry,
P. Roy,
I. M. Jones, and D. I. Stuart.
1995.
Crystal structure of SIV matrix antigen and implications for virus assembly.
Nature
378:743-747[Medline].
|
| 38.
|
Rey, O.,
J. Canon, and P. Krogstad.
1996.
HIV-1 Gag protein associates with F-actin present in microfilaments.
Virology
220:530-534[Medline].
|
| 39.
| Rhee, S. S., and E. Hunter. Unpublished
results.
|
| 40.
|
Rhee, S. S., and E. Hunter.
1987.
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.
J. Virol.
61:1045-1053[Abstract/Free Full Text].
|
| 41.
|
Rhee, S. S., and E. Hunter.
1990.
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus.
Cell
63:77-86[Medline].
|
| 42.
|
Rhee, S. S., and E. Hunter.
1990.
Structural role of the matrix protein of type D retroviruses in Gag polyprotein stability and capsid assembly.
J. Virol.
64:4383-4389[Abstract/Free Full Text].
|
| 43.
|
Rhee, S. S., and E. Hunter.
1991.
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport, and membrane-association of a capsid.
EMBO J.
10:535-546[Medline].
|
| 44.
|
Sakalian, M.,
S. D. Parker,
R. A. Weldon, Jr., and E. Hunter.
1996.
Synthesis and assembly of retrovirus gag precursors into immature capsids in vitro.
J. Virol.
70:3706-3715[Abstract].
|
| 45.
|
Sasaki, H.,
M. Nakamura,
T. Ohno,
Y. Matsuda,
Y. Yuda, and Y. Nonomura.
1995.
Myosin-actin interaction plays an important role in human immunodeficiency virus type 1 release from host cells.
Proc. Natl. Acad. Sci. USA
92:2026-2030[Abstract/Free Full Text].
|
| 46.
|
Satake, M., and R. B. Luftig.
1982.
Microtubule-depolymerizing agents inhibit Moloney leukemia virus production.
J. Gen. Virol.
58:339-349[Abstract/Free Full Text].
|
| 47.
|
Schultz, A.,
L. E. Henderson, and S. Oroszlan.
1988.
Fatty acylation of proteins.
Annu. Rev. Cell Biol.
4:611-647.
|
| 48.
|
Schultz, A. M.,
E. H. Rabin, and S. Oroszlan.
1979.
Post-translational modification of Rauscher leukemia virus precursor polyproteins encoded by the gag gene.
J. Virol.
30:255-266[Abstract/Free Full Text].
|
| 49.
|
Schultz, A. M., and A. Rein.
1983.
Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events.
J. Virol.
63:2370-2373.
|
| 50.
|
Sommerfelt, M. A.,
S. S. Rhee, and E. Hunter.
1992.
Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity.
J. Virol.
66:7005-7011[Abstract/Free Full Text].
|
| 51.
|
Stewart, L.,
G. Schatz, and V. M. Vogt.
1990.
Properties of avian retroviral particles defective in viral protease.
J. Virol.
64:5076-5092[Abstract/Free Full Text].
|
| 52.
|
Todd, M. J.,
P. V. Viitanen, and G. H. Lorimer.
1994.
Dynamics of the chaperonin ATPase cycle: implications for facilitated protein folding.
Science
265:659-666[Abstract/Free Full Text].
|
| 53.
|
Trinchieri, G., and M. De Marchi.
1975.
Antibody-dependent cell-mediated cytotoxicity in humans. II. Energy requirement.
J. Immunol.
115:256-260[Abstract/Free Full Text].
|
| 54.
|
Weldon, R. A., Jr.,
C. R. Erdie,
M. G. Oliver, and J. W. Wills.
1990.
Incorporation of chimeric Gag protein into retroviral particles.
J. Virol.
64:4169-4179[Abstract/Free Full Text].
|
| 55.
|
Weldon, R. A., Jr., and E. Hunter.
1996.
Molecular requirements for retrovirus assembly, p. 381-410. In
W. Chiu, R. M. Burnett, and R. L. Garcea (ed.), Structural biology of viruses.
Oxford University Press, New York, N.Y.
|
| 56.
|
Weldon, R. A., Jr., and J. W. Wills.
1993.
Characterization of a small (25-kDa) derivative of the Rous sarcoma virus Gag protein competent for particle release.
J. Virol.
67:5550-5561[Abstract/Free Full Text].
|
| 57.
|
Wills, J. W.,
C. E. Cameron,
C. B. Wilson,
Y. Xiang,
R. P. Bennett, and J. Leis.
1994.
An assembly domain of the Rous sarcoma virus Gag protein required late in budding.
J. Virol.
68:6605-6618[Abstract/Free Full Text].
|
| 58.
|
Wills, J. W., and R. C. Craven.
1991.
Form, function, and use of retroviral Gag proteins.
AIDS
5:639-654[Medline].
|
| 59.
| Yasuda, J., and E. Hunter. A proline-rich motif
(PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a
maturation-independent role in virion release. J. Virol., in press.
|
| 60.
|
Zhou, W.,
L. J. Parent,
J. W. Wills, and M. D. Resh.
1994.
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
J. Virol.
68:2556-2569[Abstract/Free Full Text].
|
| 61.
|
Zhou, W., and M. D. Resh.
1996.
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein.
J. Virol.
70:8540-8548[Abstract].
|
J Virol, April 1998, p. 3098-3106, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gurer, C., Hoglund, A., Hoglund, S., Luban, J.
(2005). ATP{gamma}S Disrupts Human Immunodeficiency Virus Type 1 Virion Core Integrity. J. Virol.
79: 5557-5567
[Abstract]
[Full Text]
-
Klein, K. C., Polyak, S. J., Lingappa, J. R.
(2004). Unique Features of Hepatitis C Virus Capsid Formation Revealed by De Novo Cell-Free Assembly. J. Virol.
78: 9257-9269
[Abstract]
[Full Text]
-
Morikawa, Y., Goto, T., Momose, F.
(2004). Human Immunodeficiency Virus Type 1 Gag Assembly through Assembly Intermediates. J. Biol. Chem.
279: 31964-31972
[Abstract]
[Full Text]
-
Dooher, J. E., Lingappa, J. R.
(2004). Conservation of a Stepwise, Energy-Sensitive Pathway Involving HP68 for Assembly of Primate Lentivirus Capsids in Cells. J. Virol.
78: 1645-1656
[Abstract]
[Full Text]
-
Gottwein, E., Bodem, J., Muller, B., Schmechel, A., Zentgraf, H., Krausslich, H.-G.
(2003). The Mason-Pfizer Monkey Virus PPPY and PSAP Motifs Both Contribute to Virus Release. J. Virol.
77: 9474-9485
[Abstract]
[Full Text]
-
Gurer, C., Cimarelli, A., Luban, J.
(2002). Specific Incorporation of Heat Shock Protein 70 Family Members into Primate Lentiviral Virions. J. Virol.
76: 4666-4670
[Abstract]
[Full Text]
-
Tritel, M., Resh, M. D.
(2001). The Late Stage of Human Immunodeficiency Virus Type 1 Assembly Is an Energy-Dependent Process. J. Virol.
75: 5473-5481
[Abstract]
[Full Text]
-
Mirazimi, A., Svensson, L.
(2000). ATP Is Required for Correct Folding and Disulfide Bond Formation of Rotavirus VP7. J. Virol.
74: 8048-8052
[Abstract]
[Full Text]
-
Nemergut, M. E., Macara, I. G.
(2000). Nuclear Import of the Ran Exchange Factor, Rcc1, Is Mediated by at Least Two Distinct Mechanisms. JCB
149: 835-850
[Abstract]
[Full Text]
-
Cobbold, C., Brookes, S. M., Wileman, T.
(2000). Biochemical Requirements of Virus Wrapping by the Endoplasmic Reticulum: Involvement of ATP and Endoplasmic Reticulum Calcium Store during Envelopment of African Swine Fever Virus. J. Virol.
74: 2151-2160
[Abstract]
[Full Text]
-
Chi, J. H. I., Wilson, D. W.
(2000). ATP-Dependent Localization of the Herpes Simplex Virus Capsid Protein VP26 to Sites of Procapsid Maturation. J. Virol.
74: 1468-1476
[Abstract]
[Full Text]
-
Parker, S. D., Hunter, E.
(2000). A Cell-Line-Specific Defect in the Intracellular Transport and Release of Assembled Retroviral Capsids. J. Virol.
74: 784-795
[Abstract]
[Full Text]
-
Sakalian, M., Hunter, E.
(1999). Separate Assembly and Transport Domains within the Gag Precursor of Mason-Pfizer Monkey Virus. J. Virol.
73: 8073-8082
[Abstract]
[Full Text]
-
Choi, G., Park, S., Choi, B., Hong, S., Lee, J., Hunter, E., Rhee, S. S.
(1999). Identification of a Cytoplasmic Targeting/Retention Signal in a Retroviral Gag Polyprotein. J. Virol.
73: 5431-5437
[Abstract]
[Full Text]
-
Lee, Y.-M., Liu, B., Yu, X.-F.
(1999). Formation of Virus Assembly Intermediate Complexes in the Cytoplasm by Wild-Type and Assembly-Defective Mutant Human Immunodeficiency Virus Type 1 and Their Association with Membranes. J. Virol.
73: 5654-5662
[Abstract]
[Full Text]
-
Le Blanc, I., Rosenberg, A. R., Dokhélar, M.-C.
(1999). Multiple Functions for the Basic Amino Acids of the Human T-Cell Leukemia Virus Type 1 Matrix Protein in Viral Transmission. J. Virol.
73: 1860-1867
[Abstract]
[Full Text]
-
Dasgupta, A., Wilson, D. W.
(1999). ATP Depletion Blocks Herpes Simplex Virus DNA Packaging and Capsid Maturation. J. Virol.
73: 2006-2015
[Abstract]
[Full Text]
-
Campbell, S., Rein, A.
(1999). In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain. J. Virol.
73: 2270-2279
[Abstract]
[Full Text]